跳至主要内容

The discovery stage plays a pivotal role in shaping the success of a drug development program, impacting efficiency, cost and long-term outcomes. However, challenges such as high attrition rates, complex biological targets and the right candidate selection can create significant hurdles. Implementing a robust de-risking strategy means that only the most promising compounds advance, while partnering with a trusted laboratory optimizes resource allocation, accelerates development and enhances the likelihood of success.

筛选出您的最佳候选药物并快速开始IND

Collaborating with Labcorp provides a strategic edge by enabling smarter decision-making, minimizing risks and accelerating progress. Our comprehensive discovery solutions support rapid study initiation, timely data delivery and expert scientific guidance to drive informed decisions and improve success rates. Whether you're developing small molecules, biologics or advanced therapies, we help advance your top candidates from hit validation to selection and beyond.

  • Extend your team’s expertise with scientific collaboration and insights

  • Improve probability of success with trusted data and insightful data interpretation delivered rapidly

  • Accelerate your program at scale with our global capabilities delivered with urgency

药物筛选能力

了解分子的功效以及化合物的代谢和药代动力学特征,同时提前预测和应对药物筛选挑战。

药理学
DMPK
Safety Toxicology

关键治疗专长

我们的科学带头人以数十年的专业知识为基础,提供有价值的见解,并致力于提供高质量的数据,满足您的时间要求。

肿瘤学
呼吸系统疾病
传染病

模式专长

减少研发各阶段的时间和风险,创造定制的抗体试剂,获得全面的药物筛选疫苗测试服务。

细胞与基因疗法
抗体
疫苗

资产收购与退出

When your business goal is to exit, invest or partner, you can kick-start strategic conversations with the help of MarketPlace.

  • Expand your network by accessing our innovative platform that connects asset providers with asset seekers
  • 通过加速战略对话更快地实现合作目标
  • 最大程度发挥合作努力的价值;每月建立有效的联系
EBOOK

BLOG

Unlock the 3 keys to drug discovery success

Learn how to fast-track development of your discovery phase therapeutic to the next inflection point in a cost-efficient manner, derisk it and demonstrate the value needed to attract future investment.

NOW AVAILABLE

Patient-derived xenograft models

Improve your therapeutic efficacy predictions with our fully characterized patient-derived xenografts (PDX) representing multiple histotypes.

手册

疫苗开发测试

Leverage our scientific capabilities and experience for your next vaccine development project to save time and money.

常见问题

Yes, we have BSL-2 space at our facilities in Ann Arbor, MI, and Denver, PA, and can work with a wide range of infectious agents. Learn more about our infectious disease and vaccine capabilities.

Yes, our discovery and safety teams work closely to efficiently run a study with efficacy, safety and PK, all under one roof. Explore our drug metabolism and pharmacokinetics (DMPK) solutions.

Yes, we have an inhalation delivery team at our Huntingdon site that can administer drug by the inhalation route for evaluation of efficacy, PK and safety.

Discovery DMPK screening can be done in a cost-effective manner. By leveraging technologies and resources, you can quickly and efficiently identify potential drug candidates with the desired pharmacokinetic properties. Learn about our in vitro screening capabilities.

Yes. Because our discovery teams are closely associated with safety teams, we can readily run combined studies that capture all these endpoints, allowing you to be more efficient investigating your discovery compounds.

Yes, we offer a wide range of non-GLP animal telemetry models to test your tool compound on blood pressure, ECG and cardiac function to help understand the cardiovascular risk. Explore cardiovascular safety assessments.

Explore nonclinical solutions for each stage of your drug development journey

Ready to Discover the One?